A finding of atrial fibrillation should always beg the question of its aetiology. Generations of medical students have been taught that the most common causes are rheumatic or ischaemic heart disease and hyperthyroidism, and that in a distinct minority, known as "lone" atrial fibrillators, there is no apparent reason for the arrhythmia. To a large extent recent epidemiological studies from Framingham' have confirmed this teaching, identifying rheumatic heart disease and cardiac failure as the cardiovascular disorders which most often lead to atrial fibrillation, with hypertension, coronary heart disease, and stroke being less likely to do so. Most patients with these causes of atrial fibrillation can be identified readily by careful history, clinical examination, chest radiography, electrocardiogram, and echocardiogram-the investigations which should form the basis ofassessment of all patients with this arrhythmia.
An important omission in the discussion of the Framingham analysis and the accompanying leading article2 was the absence of consideration of hyperthyroidism as a factor in their patients with "lone" atrial fibrillation (310% of the total). Atrial fibrillation develops in 10% to 150/0 of patients with overt hyperthyroidism,3 and is most common in those aged over 60, reflecting both a reduction in the threshold for atrial fibrillation with age and an increase in the prevalence of coexisting ischaemic and other forms of heart disease. Though the electrophysiological basis for atrial fibrillation is poorly understood,4 in hyperthyroidism the shortened duration of the action potential probably increases electrical excitability within the atrium and so predisposes to the arrhythmia.5
The clinical diagnosis of hyperthyroidism is not always obvious in elderly patients, in whom atrial fibrillation may be the dominant feature in the absence of goitre, classic eye In practice, most families have at least one working parent so that the recommendation is probably implemented only rarely-but the difference between the risk of one in 2-5 million doses for contacts and one in 5 million for recipients is a negligible improvement, especially if the risk of vaccineassociated poliomyelitis (like the natural disease) rises with age. Inactivated polio vaccines are said to be safer, but immunity takes somewhat longer to develop, and they cannot be recommended for vaccination of contacts, with either the vaccine or the wild virus.
